A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

Key facts

Sponsor

Janssen Research & Development, LLC

Principal Investigator

Janssen Research and Development, LLC Clinical Trial

Janssen Research and Development LLC

Intervention

Talquetamab(drug)

Enrollment

74 enrolled

Eligibility

18 years · All sexes

Timeline

2022 – 2027

Study locations (19)

• Colorado Blood Cancer Institute, Denver, Colorado, United States
• The Blavatnik Family Chelsea Medical Center at Mount Sinai, New York, New York, United States
• Icahn School of Medicine at Mount Sinai, New York, New York, United States
• Memorial Sloan Kettering Cancer Center, New York, New York, United States
• Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States
• Sarah Cannon Research Institute, Nashville, Tennessee, United States
• Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States
• CHU de Montpellier Hopital Saint Eloi, Montpellier, France
• CHU de Nantes hotel Dieu, Nantes, France
• CHU Poitiers - Hopital la Miletrie, Poitiers, France
• Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
• Universitatsklinikum Carl Gustav Carus Dresden, Dresden, Germany
• Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
• Universitaetsklinikum Heidelberg, Heidelberg, Germany
• Universitatsklinikum Wurzburg, Würzburg, Germany
• +4 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Paraneoplastic cerebellar degeneration

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07144280
  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
  Pfizer
• RECRUITINGNCT06965166
  Contrast-Enhanced Photon-Counting Detector CT (PCD-CT) for the Local Staging of Rectal Cancer
  Mayo Clinic
• ACTIVE NOT RECRUITINGPHASE2NCT05557591
  A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
  Regeneron Pharmaceuticals
• RECRUITINGNANCT06080841
  Curcumin Supplementation in Cervical Cancer
  National Institute of Cancerología

See all trials for Paraneoplastic cerebellar degeneration →